---
title: Treatment of myelodysplastic syndromes
date: '2023-10-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37874917/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231025180748&v=2.17.9.post6+86293ac
source: Blood
description: The myelodysplastic syndromes (MDS) constitute a profoundly heterogeneous
  myeloid malignancy with a common origin in the hemopoietic stem cell compartment.
  Consequently, patient management and treatment are as heterogeneous. Decision-making
  includes identifying risk, symptoms, and options for the individual patient and
  to make a risk-benefit analysis. The only potential cure is allogeneic stem cell
  transplantation and albeit the fraction of transplanted MDS patients increase over
  time due to ...
disable_comments: true
---
The myelodysplastic syndromes (MDS) constitute a profoundly heterogeneous myeloid malignancy with a common origin in the hemopoietic stem cell compartment. Consequently, patient management and treatment are as heterogeneous. Decision-making includes identifying risk, symptoms, and options for the individual patient and to make a risk-benefit analysis. The only potential cure is allogeneic stem cell transplantation and albeit the fraction of transplanted MDS patients increase over time due to ...